Zimmer Biomet’s cervical disc implant labeling features 7-year clinical results: 5 things to know

The FDA granted Zimmer Biomet’s request to extend its Mobi-C Cervical Disc labeling to include seven-year clinical results.

Advertisement

Here are five things to know:

1. The results are consistent with Zimmer Biomet’s findings at two and five years.

2. At the seven-year mark, Zimmer Biomet found the Mobi-C disc was successful for two-level use when compared to anterior cervical discectomy and fusion.

3. Zimmer Biomet followed nearly 600 patients who were implanted with the Mobi-C disc for seven years. The study showed the disc was associated with lower pain scores. Patients maintained range of motion and fewer subsequent surgeries were necessary.

4. The Mobi-C is a cobalt chromium alloy and polyethylene mobile-bearing prosthesis that is inserted in a single step, without requiring bone chiseling to accommodate vertebral anchorage such as screws or keels.

5. The Mobi-C is the first cervical disc prothesis approved by the FDA for cervical disc reconstruction at one and two levels.

More articles on devices and implants:
Stryker to pay $7.8M to settle SEC Foreign Corrupt Practices Act violation charge: 5 things to know
Global thoracolumbar spine devices market to grow at 6.5% CAGR through 2023
4 things to know about RTI Surgical’s CEO

At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.

Advertisement

Next Up in Spinal Tech

Advertisement

Comments are closed.